uk recell trial, page-10

This is what Andrew Cannon says when I queried him regarding CCE's price and CellSpray issue.
---------------------------------------------
There is no underlying reason behind the share
price movement other than general market weakness and tax loss selling may well be having an impact. CellSpray continues to be used in Europe (we are focusing on Germany) with good outcomes and hospitals are reordering the product which indicates they are happy with the outcomes. As we have stated we will be concentrating on key approved markets to
generate the sales forecasts we announced in March.
---------------------------------------------------